These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15778428)

  • 21. The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab.
    Wu B; Joshi A; Ren S; Ng C
    J Pharm Sci; 2006 Jun; 95(6):1258-68. PubMed ID: 16637054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efalizumab.
    Wellington K; Perry CM
    Am J Clin Dermatol; 2005; 6(2):113-8; discussion 119-20. PubMed ID: 15799683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.
    Ng CM; Joshi A; Dedrick RL; Garovoy MR; Bauer RJ
    Pharm Res; 2005 Jul; 22(7):1088-100. PubMed ID: 16028009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
    Leonardi CL; Papp KA; Gordon KB; Menter A; Feldman SR; Caro I; Walicke PA; Compton PG; Gottlieb AB;
    J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):425-33. PubMed ID: 15761420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efalizumab-associated papular psoriasis.
    Hassan AS; Simon D; Simon HU; Braathen LR; Yawalkar N
    Arch Dermatol; 2007 Jul; 143(7):900-6. PubMed ID: 17638735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exacerbation of psoriasis under efalizumab therapy.
    Rallis E; Verros C; Karanikola E; Valaskatzi A; Papaconstantis M
    J Cutan Med Surg; 2009; 13(2):106-9. PubMed ID: 19298780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis.
    Jauslin P; Kulkarni P; Li H; Vatakuti S; Hussain A; Wenning L; Kerbusch T
    Clin Pharmacokinet; 2019 Aug; 58(8):1059-1068. PubMed ID: 30915660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
    Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
    Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
    Papp KA; Miller B; Gordon KB; Caro I; Kwon P; Compton PG; Leonardi CL;
    J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S164-70. PubMed ID: 16488338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efalizumab: continuous therapy for chronic psoriasis.
    Cather JC; Menter A
    Expert Opin Biol Ther; 2005 Mar; 5(3):393-403. PubMed ID: 15833076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of hand and foot psoriasis with efalizumab therapy.
    Fretzin S; Crowley J; Jones L; Young M; Sobell J
    J Drugs Dermatol; 2006 Oct; 5(9):838-46. PubMed ID: 17039648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience.
    Langley RG; Carey WP; Rafal ES; Tyring SK; Caro I; Wang X; Wetherill G; Gordon KB
    Clin Ther; 2005 Sep; 27(9):1317-28. PubMed ID: 16291408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital.
    Antoniou C; Stefanaki I; Stratigos A; Avgerinou G; Stavropoulos P; Potouridou I; Polidorou D; Moustou AE; Kosmadaki M; Katsambas AD
    Br J Dermatol; 2007 Apr; 156 Suppl 2():12-6. PubMed ID: 17371318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efalizumab: an overview.
    Leonardi CL
    J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S98-104. PubMed ID: 12894132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab.
    Cather JC; Cather JC; Menter A
    Expert Opin Biol Ther; 2003 Apr; 3(2):361-70. PubMed ID: 12662148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: a case study.
    Gisondi P; Giglio MD; Girolomoni G
    J Dermatolog Treat; 2006; 17(3):172-5. PubMed ID: 16854760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis.
    Zhu YW; Mendelsohn A; Pendley C; Davis HM; Zhou H
    Int J Clin Pharmacol Ther; 2010 Dec; 48(12):830-46. PubMed ID: 21084039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody.
    Papp K; Bissonnette R; Krueger JG; Carey W; Gratton D; Gulliver WP; Lui H; Lynde CW; Magee A; Minier D; Ouellet JP; Patel P; Shapiro J; Shear NH; Kramer S; Walicke P; Bauer R; Dedrick RL; Kim SS; White M; Garovoy MR
    J Am Acad Dermatol; 2001 Nov; 45(5):665-74. PubMed ID: 11606914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute.
    Ferrándiz C; Carrascosa JM
    Br J Dermatol; 2007 Apr; 156 Suppl 2():24-9. PubMed ID: 17371320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.